Quartz Partners LLC Sells 6,492 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Quartz Partners LLC trimmed its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 14.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 37,519 shares of the company’s stock after selling 6,492 shares during the quarter. Quartz Partners LLC’s holdings in Elanco Animal Health were worth $454,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the stock. DDD Partners LLC purchased a new position in Elanco Animal Health during the 4th quarter valued at about $5,974,000. Geode Capital Management LLC grew its stake in Elanco Animal Health by 0.8% during the third quarter. Geode Capital Management LLC now owns 7,868,675 shares of the company’s stock valued at $115,623,000 after acquiring an additional 65,303 shares in the last quarter. Atom Investors LP increased its holdings in Elanco Animal Health by 310.3% during the 3rd quarter. Atom Investors LP now owns 345,855 shares of the company’s stock worth $5,081,000 after acquiring an additional 261,559 shares during the period. Harbor Capital Advisors Inc. lifted its stake in Elanco Animal Health by 24.0% in the 4th quarter. Harbor Capital Advisors Inc. now owns 1,084,629 shares of the company’s stock worth $13,135,000 after purchasing an additional 209,734 shares in the last quarter. Finally, Wellington Management Group LLP boosted its holdings in Elanco Animal Health by 19.2% in the 3rd quarter. Wellington Management Group LLP now owns 4,007,805 shares of the company’s stock valued at $58,875,000 after purchasing an additional 646,522 shares during the period. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Trading Down 1.0 %

NYSE ELAN opened at $11.02 on Monday. The firm has a market cap of $5.45 billion, a PE ratio of 27.54, a price-to-earnings-growth ratio of 2.50 and a beta of 1.42. Elanco Animal Health Incorporated has a 1-year low of $10.77 and a 1-year high of $18.80. The stock has a 50-day moving average of $11.80 and a 200-day moving average of $13.10. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66.

Analysts Set New Price Targets

Several research firms have recently weighed in on ELAN. Morgan Stanley decreased their price target on shares of Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 29th. Barclays upped their price objective on shares of Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, November 8th. UBS Group started coverage on shares of Elanco Animal Health in a report on Monday, December 9th. They issued a “buy” rating and a $18.00 price target on the stock. Leerink Partners initiated coverage on Elanco Animal Health in a research note on Monday, December 2nd. They issued a “market perform” rating and a $14.00 target price on the stock. Finally, Stifel Nicolaus dropped their target price on Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Friday. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $16.00.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.